Anna Vardanyan, MD, PhD

Anna Vardanyan serves as Vice President of Business Development of Inmagene Biopharmaceuticals. Dr. Vardanyan brings more than 15 years of experience in R&D and business development. She has a proven track record in executing business development transactions, encompassing key regions such as the US, the EU, and Asia, spanning a wide spectrum of therapeutic areas. Dr. Vardanyan’s expertise extends across deal sourcing, leading cross-functional due-diligence efforts, deal structuring, negotiation, and alliance management. Before joining Inmagene, she served as Executive Director of Business Development at Turning Point Therapeutics, which was subsequently acquired by Bristol Myers Squibb (BMS). Dr. Vardanyan also served as Executive Director of Business Development and Alliance Management at Everest Medicines and Director of Due Diligence, BDL, at Sanofi and contributed to various roles in R&D with increasing responsibilities at Genzyme and Sanofi. She has a PhD in medical pharmacology from the University of Arizona and an MD from Yerevan State Medical University.